{'fraction_non_alphanumeric': 0.031026252983293555, 'fraction_numerical': 0.050119331742243436, 'mean_word_length': 4.6, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The new antidepressant zimeldine in general practice. A surveillance study of 15,000 patients

ABSTRACT— The safety and efficacy of zimeldine – the 5‐HT reuptake blocker – was investigated in a 3‐week open surveillance study of 15,000 out‐patients with depressive illness. In general, a single daily dose of 200 mg of zimeldine was given to adults for a minimum of 3 weeks. Patients of 65 years or over received 100 mg.